Novel Therapeutic for Pulmonary Arterial Hypertension
Novel Therapeutic for Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) has limited treatment options with 40-50% mortality within 3 years of diagnosis.
Identification of novel therapeutic targets remains a critical unmet medical need for this disease.
The global market for PAH is expected to grow to over $3.5 billion by 20161. • MicroRNAs (miRs) 424 and 503 are effective in human and animal models of PAH (see figure).
miRs 424 and 503 may be the basis for effective therapeutics for PAH.
